Incyte Corp. Common Stock (INCY)

About INCY

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acut…

Sector

Health Care

Industry

Biotechnology: Commercial Physical & Biological Resarch

Employees

2,844

Website

www.incyte.com/

Fundamentals

1-day range

$123.08$127.74

Market cap

$24.01B

P/E (trailing)

15.14

P/E (forward)

13.91

EPS (trailing)

$7.85

Dividend yield

—

Beta

0.74

Avg. volume

1.87M

Forecasts

24 analyst ratings

Incyte Corp. Common Stock Competitors

Chosen by industry and closest market cap.

• INCY

  Incyte Corp. Common Stock

  $124.39

  ▼ 2.63%
  Market cap $24.01BP/E 15.14
  $81.09$132.6
• MEDP

  Medpace Holdings Inc. Common Stock

  $599.99

  ▼ 1.89%
  Market cap $16.00BP/E 33.13
  $373$677.9
• ICLR

  ICON plc Ordinary Shares

  $169.84

  ▲ 0.07%
  Market cap $12.13BP/E 183.55
  $66.57$203.91
• CRL

  Charles River Laboratories International Inc. Common Stock

  $291.74

  ▼ 1.58%
  Market cap $11.12BP/E —
  $144.26$303.31
• IQV

  IQVIA Holdings Inc. Common Stock

  $261.54

  ▼ 0.32%
  Market cap $38.41BP/E 28.64
  $154.5$265.25
• ABSI

  Absci Corporation Common Stock

  $8.72

  ▼ 7.43%
  Market cap $1.24BP/E —
  $2.24$12.06
• ONMD

  OneMedNet Corp Class A Common Stock

  $0.5801

  ▼ 0.84%
  Market cap $43.24MP/E —
  $0.49$4.22

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• TG Therapeutics: Briumvi's Growth Attracts Buyout Rumors
  SeekingAlpha · 8/22/2026
• Here’s How Much You Would Have Made Owning Incyte Stock In The Last 20 Years
  benzinga · 8/20/2026
• Here’s How Much You Would Have Made Owning Incyte Stock In The Last 20 Years
  Benzinga · 8/20/2026
• Canaccord Genuity Initiates Coverage On Incyte with Buy Rating, Announces Price Target of $152
  Benzinga · 8/20/2026
• Here Are Thursday’s Top Wall Street Analyst Research Calls: Alphabet, Analog Devices, Crown Castle, ebay, EPR Properties, Etsy, Merck & Co., Shopify, TJX Companies, and More
  Yahoo · 8/20/2026
• Tempus AI Just Had Their Entire Strategy Validated By Moderna's Vaccine Advance
  SeekingAlpha · 8/20/2026
• HC Wainwright & Co. Reiterates Buy on Incyte, Maintains $150 Price Target
  Benzinga · 8/20/2026
• 7 Growth Stocks Holding Up in a Tough Market
  Yahoo · 8/20/2026
• Silence Therapeutics: Making Some Recent Noise
  SeekingAlpha · 8/19/2026

• Pablo J. Cagnoni · August 12, 2026 · Sale

  10.8K @ $120.04
• Patrick A. Mayes · August 5, 2026 · Option Exercise

  2.2K @ $106.47
• Patrick A. Mayes · August 5, 2026 · Sale

  2.2K @ $123.99
• Pablo J. Cagnoni · August 5, 2026 · Sale

  10.6K @ $122.69
• Patrick A. Mayes · August 3, 2026 · Option Exercise

  6.1K @ $105.43
• Patrick A. Mayes · August 3, 2026 · Sale

  6.1K @ $120.43
• Patrick A. Mayes · July 31, 2026 · Option Exercise

  326 @ $105.43
• Patrick A. Mayes · July 31, 2026 · Option Exercise

  85 @ $106.47
• Patrick A. Mayes · July 31, 2026 · Option Exercise

  2.3K @ $90.56
• Patrick A. Mayes · July 31, 2026 · Option Exercise

  1.6K @ $85.01
• Patrick A. Mayes · July 31, 2026 · Option Exercise

  2.6K @ $74.78
• Patrick A. Mayes · July 31, 2026 · Option Exercise

  3.0K @ $83.2
• Patrick A. Mayes · July 31, 2026 · Option Exercise

  1.6K @ $80.5
• Patrick A. Mayes · July 31, 2026 · Option Exercise

  2.9K @ $77.67
• Patrick A. Mayes · July 31, 2026 · Option Exercise

  9.5K @ $72.27

Institutional Ownership

March 31, 2026

Total shares held

192.63M

Total value held

$17.30B

Institutional holders

800